Table 1.
Baseline Characteristics of Participants in Anatomical and Viability-Guided Completeness of Revascularization Analyses
| REVIVED-BCIS2 Trial (n = 700) | Anatomical CoR Analysis (n = 670) | Viability-Guided CoR Analysis (n = 619) | |
|---|---|---|---|
| Age, y | 69.4 ± 9.1 | 69.2 ± 9.1 | 69.1 ± 9.0 |
| Male | 614 (87.7) | 587 (87.6) | 544 (87.9) |
| Body mass index, kg/m2 | 28.0 (24.7-31.7) | 28.1 (24.9-31.9) | 28.1 (24.9-32.0) |
| Diabetes | 289 (41.3) | 277 (41.3) | 260 (42.0) |
| Hypertension | 391 (55.9) | 378 (56.5) | 348 (56.3) |
| Current or previous smoker | 510 (72.9) | 490 (73.1) | 454 (73.3) |
| Cerebrovascular disease | 84 (12.0) | 81 (12.1) | 70 (11.3) |
| Peripheral vascular disease | 94 (13.4) | 90 (13.4) | 85 (13.7) |
| Racea | |||
| Asian | 49 (7.0) | 47 (7.0) | 40 (6.5) |
| Black | 6 (0.9) | 6 (0.9) | 6 (1.0) |
| Mixed, other, or not reported | 11 (1.6) | 11 (1.6) | 10 (1.6) |
| White | 634 (90.6) | 606 (90.4) | 563 (91.0) |
| History of myocardial infarction | 372 (53.1) | 356 (53.1) | 327 (52.8) |
| Hospitalization for heart failure in previous 2 y | 233 (33.3) | 221 (33.0) | 213 (34.4) |
| Previous PCI | 142 (20.3) | 136 (20.3) | 121 (19.5) |
| Previous CABG | 34 (4.9) | 33 (4.9) | 31 (5.0) |
| CCS angina class | |||
| 0 | 464 (66.6) | 448 (67.2) | 418 (67.9) |
| 1 | 143 (20.5) | 137 (20.5) | 126 (20.5) |
| 2 | 75 (10.8) | 70 (10.5) | 61 (9.9) |
| 3 | 14 (2.0) | 12 (1.8) | 11 (1.8) |
| 4 | 1 (0.1) | 0 (0.0) | 0 (0.0) |
| NYHA functional class | |||
| I | 126 (18.1) | 121 (18.2) | 115 (18.7) |
| II | 387 (55.7) | 373 (56.1) | 347 (56.5) |
| III | 172 (24.7) | 163 (24.5) | 145 (23.6) |
| IV | 10 (1.4) | 8 (1.2) | 7 (1.1) |
| Cardiac medication | |||
| RAAS inhibitor | 584 (83.5) | 557 (83.3) | 511 (82.7) |
| Beta-blocker | 634 (90.6) | 608 (90.7) | 561 (90.6) |
| MRA | 364 (49.4) | 332 (49.6) | 308 (49.8) |
| Baseline BCIS jeopardy scoreb | 8 (6-10) | 8 (6-10) | 8 (6-10) |
| Post-PCI BCIS jeopardy score | 2 (0-4) | 2 (0-4) | 2 (0-4) |
| Baseline SYNTAX score | 22.0 (15.0-28.5) | 22.0 (15.0-28.5) | 22.0 (15.0-29.0) |
| Residual SYNTAX score | 8.0 (2.0-14.0) | 8.0 (2.0-14.0) | 8.0 (2.0-14.0) |
| ICD with or without CRT at randomization | 148 (21.1) | 140 (20.9) | 129 (20.8) |
| Left main coronary artery disease | 95 (13.6) | 88 (13.2) | 85 (13.8) |
| LVEF, %c | 31.9 ± 9.9 | 31.9 ± 9.8 | 32.1 ± 9.8 |
| Viability test | |||
| CMR | 479 (78.5) | 458 (78.2) | 453 (78.0) |
| DSE | 131 (21.5) | 128 (21.8) | 128 (22.0) |
| Number of viable segments | 7 (4-10) | 7 (4-10) | 7 (4-10) |
Values are mean ± SD, n (%), or median (Q1-Q3).
BCIS = British Cardiovascular Intervention Society; CABG = coronary artery bypass grafting; CCS = Canadian Cardiovascular Society; CMR = cardiovascular magnetic resonance; CoR = completeness of revascularization; CRT = cardiac resynchronization therapy; CTO = chronic total occlusion; DSE = dobutamine stress echocardiography; ICD = implantable cardioverter-defibrillator; LVEF = left ventricular ejection fraction; MRA = mineralocorticoid receptor antagonist; PCI = percutaneous coronary intervention; Q = quartile; RAAS = renin-angiotensin-aldosterone system; REVIVED-BCIS2 = Revascularization for Ischemic Ventricular Dysfunction; SYNTAX = Synergy Between PCI With Taxus and Cardiac Surgery.
Race as self-reported by participants using options defined by the investigators.
The BCIS jeopardy score is a quantification of the extent of myocardial jeopardy relating to clinically significant coronary artery stenoses. The score ranges from 0 (no significant coronary disease) to 12 (disease jeopardizing the whole left ventricular myocardium). The score presented is as calculated by the angiography core laboratory.
Baseline left ventricular ejection fraction measured by the blinded echocardiography core laboratory.